MADRIGAL PHARMACEUTICALS, INC. (MDGL)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Product revenue, net | 212,802 | 137,250 | 62,175 | 14,638 |
| Selling, general and administrative | 196,858 | 167,876 | 107,585 | 105,448 |
| Research and development | 54,081 | 44,172 | 68,742 | 71,091 |
| Cost of sales | 9,065 | 4,513 | 2,152 | 636 |
| Total operating expenses | 260,004 | 216,561 | 178,479 | 177,175 |
| Loss from operations | -47,202 | -79,311 | -116,304 | -162,537 |
| Interest income | 8,227 | 9,370 | 13,019 | 14,222 |
| Interest expense | 3,264 | - | - | - |
| Other expense | -42 | - | - | - |
| Interest expense | - | 3,297 | 3,679 | 3,656 |
| Net loss | -42,281 | -73,238 | -106,964 | -151,971 |
| Basic net loss per common share (in dollars per share) | -1.9 | -3.32 | -4.92 | -7.1 |
| Basic weighted average number of common shares outstanding (in shares) | 22,207,017 | 22,091,314 | 21,745,929 | 21,402,646 |
| Diluted net loss per common share (in dollars per share) | -1.9 | -3.32 | -4.92 | -7.1 |
| Diluted weighted average number of common shares outstanding (in shares) | 22,207,017 | 22,091,314 | 21,745,929 | 21,402,646 |